Krogerus advised Herantis Pharma as lead counsel on its secondary listing on Nasdaq First North Growth Market Sweden as well as on the related public offering in Sweden and Denmark and private placement to institutional investors in the EEA.
Herantis Pharma is an innovative drug development company breaking the boundaries of standard therapeutic approaches. The regenerative medicine drug candidates of Herantis Pharma, CDNF and Lymfactin®, aim to revolutionise the treatment of Parkinson’s disease and other neurodegenerative diseases, and of secondary lymphedema. The shares of Herantis Pharma are listed on the Nasdaq First North Growth Market Finland and Sweden marketplaces.
The Krogerus team, led by Partner Tom Fagernäs, included senior associate Paul Raade and associates Samuli Torpisto and Ida Hellström.